Research progress on the relationship between ceramide and diabetes mellitus and its complications

doi:10.3877/cma.j.issn.2095-655X.2022.03.003

Abstract

Abstract:

Globally, 1 in 11 adults has diabetes, and the threat of diabetes to the human body is mainly its serious, sometimes life-threatening complications. Ceramide is a sphingolipid substance that plays a key role in the regulation of signal transduction pathways, which is mainly synthesized by three pathways: de novo synthesis pathway, sphingomyelin hydrolysis/degradation pathway and recovery/remediation pathway. Ceramide has been linked to the development of diabetes by inducing β cell apoptosis, insulin resistance, and inhibiting insulin gene expression. Some species or ceramide proportions of ceramide may serve as biomarkers of diabetes risk, and understanding the role of ceramides in diabetes and its complications is critical for treatment planning.This review discusses the relationship and mechanism of ceramides in the progression of diabetes and its complications, with a focus on the mechanisms of correlation between ceramides and diabetic retinopathy, diabetic nephropathy, diabetic cardiovascular disease, and diabetic neuropathy, as well as some potential and emerging treatment strategies.

Key words: Ceramides, Diabetes mellitus, Diabetic angiopathies, Diabetic retinopathy, Diabetic nephropathies

Qiyu Ran, Pengyu Du, Lei Kong, Bing Sun. Research progress on the relationship between ceramide and diabetes mellitus and its complications[J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(03): 158-162.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2022.03.003

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2022/V10/I03/158

References 47

[1]	Kim DS, Kim BC, Daily JW, et al. High genetic risk scores for impaired insulin secretory capacity doubles the risk for type 2 diabetes in Asians and is exacerbated by Western-type diets[J]．Diabetes Metab Res Rev，2018，34(1)：e2944.DOI：10.1002/dmrr.2944.
[2]	Meikle PJ，Summers SA.Sphingolipids and phospholipids in insulin resistance and related metabolic disorders[J]．Nat Rev Endocrinol，2017，13(2): 79-91.DOI：10.1038/nrendo.2016.169.
[3]	Saeedi P，Petersohn I，Salpea P，et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045：results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]．Diabetes Res Clin Pract，2019(157)：107843.DOI：10.1016/j.diabres.2019.107843.
[4]	Vasiliauskaité-Brooks I, Sounier R, Rochaix P, et al. Structural insights into adiponectin receptors suggest ceramidase activity[J]．Nature，2017，544(7648)：120-123.DOI：10.1038/nature21714.
[5]	Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy[J]．Nat Rev Cancer，2018，18(1)：33-50.DOI：10.1038/nrc.2017.96.
[6]	Hannun YA，Obeid LM.Sphingolipids and their metabolism in physiology and disease[J]．Nat Rev Mol Cell Biol，2018，19(3)：175-191.DOI：10.1038/nrm.2017.107.
[7]	Galadari S，Rahman A，Pallichankandy S，et al.Role of ceramide in diabetes mellitus: evidence and mechanisms[J]．Lipids Health Dis，2013(12)：98.DOI：10.1186/1476-511X-12-98.
[8]	Woo CY，Baek JY，Kim AR，et al.Inhibition of ceramide accumulation in podocytes by myriocin prevents diabetic nephropathy[J]．Diabetes Metab J，2020，44(4)：581-591.DOI: 10.4093/dmj.2019.0063.
[9]	Raichur S, Brunner B, Bielohuby M, et al. The role of C16：0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach[J]．Mol Metab，2019(21): 36-50.DOI：10.1016/j.molmet.2018.12.008.
[10]	Filippatou AG, Moniruzzaman M, Sotirchos ES, et al. Serum ceramide levels are altered in multiple sclerosis[J]．Mult Scler，2021，27(10)：1506-1519.DOI：10.1177/1352458520971816.
[11]	Garić D，De Sanctis JB，Shah J，et al.Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases：the importance of side chain[J]．Prog Lipid Res，2019(74)：130-144.DOI：10.1016/j.plipres.2019.03.001.
[12]	Chakravarthy H，Navitskaya S，O'Reilly S ，et al.Role of acid sphingomyelinase in shifting the balance between proinflammatory and reparative bone marrow cells in diabetic retinopathy[J]．Stem Cells，2016，34(4)：972-983.DOI：10.1002/stem.2259.
[13]	Pant DC，Aguilera-Albesa S，Pujol A．Ceramide signalling in inherited and multifactorial brain metabolic diseases[J]．Neurobiol Dis，2020(143)：105014.DOI：10.1016/j.nbd.2020.105014.
[14]	Morad SA，Cabot MC.Ceramide-orchestrated signalling in cancer cells[J]．Nat Rev Cancer，2013，13(1): 51-65.DOI：10.1038/nrc3398.
[15]	Castro BM，Prieto M，Silva LC.Ceramide: a simple sphingolipid with unique biophysical properties[J]．Prog Lipid Res，2014(54)：53-67.DOI: 10.1016/j.plipres.2014.01.004.
[16]	Yaribeygi H，Bo S，Ruscica M，et al.Ceramides and diabetes mellitus：an update on the potential molecular relationships[J]．Diabet Med，2020，37(1)：11-19.DOI: 10.1111/dme.13943.
[17]	Park WJ, Song JH, Kim GT, et al. Ceramide and Sphingosine 1-phosphate in liver diseases[J]．Mol Cells，2020，43(5)：419-430.DOI：10.14348/molcells.2020.0054.
[18]	Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling[J]．Cell Signal，2008，20(6): 1010-1018.DOI：10.1016/j.cellsig.2007.12.006.
[19]	Chaurasia B, Tippetts TS, Mayoral Monibas R, et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis[J]．Science，2019，365(6451): 386-392.DOI：10.1126/science.aav3722.
[20]	Xia QS，Lu FE，Wu F，et al.New role for ceramide in hypoxia and insulin resistance[J]．World J Gastroenterol，2020，26(18): 2177-2186.DOI：10.3748/wjg.v26.i18.2177.
[21]	Mandal N，Grambergs R，Mondal K，et al.Role of ceramides in the pathogenesis of diabetes mellitus and its complications[J]．J Diabetes Complications，2021，35(2)：107734.DOI：10.1016/j.jdiacomp.2020.107734.
[22]	Baranowski M，Blachnio-Zabielska A，Hirnle T，et al.Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide[J]．J Lipid Res，2010，51(1): 74-80.DOI：10.1194/jlr.M900002-JLR200.
[23]	Sugimoto M，Shimizu Y，Zhao S，et al.Characterization of the role of sphingomyelin synthase 2 in glucose metabolism in whole-body and peripheral tissues in mice[J]．Biochim Biophys Acta，2016，1861(8 Pt A)：688-702.DOI：10.1016/j.bbalip.2016.04.019.
[24]	Holland WL，Brozinick JT，Wang LP，et al.Inhibition of ceramide synthesis ameliorates glucocorticoid-，saturated-fat-，and obesity-induced insulin resistance[J]．Cell Metab，2007，5(3)：167-179.DOI：10.1016/j.cmet.2007.01.002.
[25]	Lennon R, Pons D, Sabin MA, et al. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy[J]．Nephrol Dial Transplant，2009，24(11)：3288-3296.DOI：10.1093/ndt/gfp302.
[26]	Hilvo M，Salonurmi T, Havulinna AS, et al. Ceramide stearic to palmitic acid ratio predicts incident diabetes[J]．Diabetologia，2018，61(6)：1424-1434.DOI：10.1007/s00125-018-4590-6.
[27]	Stitt AW，Lois N，Medina RJ，et al.Advances in our understanding of diabetic retinopathy[J]．Clin Sci(Lond)，2013，125(1)：1-17.DOI：10.1042/CS20120588.
[28]	Brownlee M．Biochemistry and molecular cell biology of diabetic complications[J]．Nature，2001，414(6865)：813-820.DOI：10.1038/414813a.
[29]	Opreanu M，Tikhonenko M，Bozack S，et al.The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models[J]．Diabetes，2011，60(9)：2370-2378.DOI：10.2337/db10-0550.
[30]	Levitsky Y，Hammer SS，Fisher KP，et al.Mitochondrial ceramide effects on the retinal pigment epithelium in diabetes[J]．Int J Mol Sci，2020，21(11)：3830.DOI：10.3390/ijms21113830.
[31]	Molitch ME，Adler AI，Flyvbjerg A，et al.Diabetic kidney disease: a clinical update from kidney disease：improving global outcomes[J]．Kidney Int，2015，87(1)：20-30.DOI：10.1038/ki.2014.128.
[32]	Wada J，Makino H．Inflammation and the pathogenesis of diabetic nephropathy[J]．Clin Sci(Lond)，2013，124(3)：139-152.DOI：10.1042/CS20120198.
[33]	Lang F，Ullrich S，Gulbins E．Ceramide formation as a target in beta-cell survival and function[J]．Expert Opin Ther Targets，2011，15(9)：1061-1071.DOI：10.1517/14728222.2011.588209.
[34]	Choi SR, Lim JH, Kim MY, et al. Adiponectin receptor agonist AdipoRon decreased ceramide，and lipotoxicity，and ameliorated diabetic nephropathy[J]．Metabolism，2018(85)：348-360.DOI：10.1016/j.metabol.2018.02.004.
[35]	Holland WL，Xia JY，Johnson JA，et al.Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis[J]．Mol Metab，2017，6(3)：267-275.DOI：10.1016/j.molmet.2017.01.002.
[36]	Sas KM，Nair V，Byun J，et al.Targeted lipidomic and transcriptomic analysis identifies dysregulated renal ceramide metabolism in a mouse model of diabetic kidney disease[J]．J Proteomics Bioinform，2015(14): 2.DOI：10.4172/jpb.S14-002.
[37]	Morita Y，Kurano M，Sakai E，et al.Analysis of urinary sphingolipids using liquid chromatography-tandem mass spectrometry in diabetic nephropathy[J]．J Diabetes Investig，2020，11(2)：441-449.DOI：10.1111/jdi.13154.
[38]	Klein RL，Hammad SM，Baker NL，et al.Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes[J]．Metabolism，2014，63(10)：1287-1295.DOI：10.1016/j.metabol.2014.07.001.
[39]	Peterson LR，Jiang X，Chen L，et al.Alterations in plasma triglycerides and ceramides：links with cardiac function in humans with type 2 diabetes[J]．J Lipid Res，2020，61(7)：1065-1074.DOI：10.1194/jlr.RA120000669.
[40]	Yu J，Pan W，Shi R，et al.Ceramide is upregulated and associated with mortality in patients with chronic heart failure[J]．Can J Cardiol，2015，31(3)：357-363.DOI：10.1016/j.cjca.2014.12.007.
[41]	Wang DD，Toledo E，Hruby A，et al.Plasma ceramides，mediterranean diet，and incident cardiovascular disease in the predimed trial (Prevención con Dieta Mediterránea)[J]．Circulation，2017，135(21): 2028-2040.DOI：10.1161/CIRCULATIONAHA.116.024261.
[42]	Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy[J]．Cochrane Database Syst Rev，2012，6(6)：CD007543.DOI：10.1002/14651858.CD007543.pub2.
[43]	Callaghan BC，Gallagher G，Fridman V，et al.Diabetic neuropathy: what does the future hold？[J]．Diabetologia，2020，63(5)：891-897.DOI：10.1007/s00125-020-05085-9.
[44]	Zuellig RA，Hornemann T，Othman A，et al.Deoxysphingolipids，novel biomarkers for type 2 diabetes，are cytotoxic for insulin-producing cells[J]．Diabetes，2014，63(4)：1326-1339.DOI：10.2337/db13-1042.
[45]	Hammad SM, Baker NL, El Abiad JM, et al. Increased plasma levels of select Deoxy-ceramide and ceramide species are associated with increased odds of diabetic neuropathy in type 1 diabetes: a pilot study[J]．Neuromolecular Med，2017，19(1)：46-56.DOI：10.1007/s12017-016-8423-9.
[46]	Langeslag M，Kress M．The ceramide-S1P pathway as a druggable target to alleviate peripheral neuropathic pain[J]．Expert Opin Ther Targets，2020，24(9): 869-884.DOI：10.1080/14728222.2020.1787989.
[47]	Li C，Li JN，Kays J，et al.Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3[J]．J Neuroinflammation，2015(12)：70.DOI：10.1186/s12974-015-0286-8.

Please choose a citation manager

Content to export